COMMUNIQUÉS West-GlobeNewswire

Restore Brain Highlights New Insights on How TMS Therapy Works Following Dallas Behavioral Health Summit
10/02/2026
Restore Brain executive John Cavanagh shared neuroscience-based insights on TMS during a recent behavioral health summit held in Dallas Restore Brain Logo DALLAS, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Restore Brain, a multi [...]
Fangzhou ’XingShi’ Large Language Model Highlighted Among China’s Most Anticipated Healthcare Models for 2026
10/02/2026
SHANGHAI, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Industry research platform VBData recently highlighted “XingShi” Large Language Model (“XS LLM”) from Fangzhou Inc. ("Fangzhou" or the "Company") (HKEX: 06086), a leader in AI [...]
Propr® Launches Propr Picks: Innovative Floss Picks to Elevate Daily Oral Care
10/02/2026
NEW YORK, NY, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Propr ®, the fluoride free oral care brand founded by acclaimed periodontist Dr. Jack Gruber , today announced the launch of Propr Picks , a thoughtfully engineered dental [...]
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
09/02/2026
WATERTOWN, Mass., Feb. 09, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced [...]
DBV Technologies participeà la conférence Emerging Outlook: Biotech Summit organisée par Guggenheim Securities
09/02/2026
Châtillon, France, le 9 février (22 :30 CET) 2026 DBV Technologies participeà la conférence Emerging Outlook: Biotech Summit organisée par Guggenheim Securities DBV Technologies (Euronext : DBV – ISIN : FR0010417345 – [...]
SpyGlass Pharma Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
09/02/2026
ALISO VIEJO, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma”), a late-stage biopharmaceutical company, today announced the closing of its initial public offering of 10, [...]
Praxis Precision Medicines to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 19, 2026, and Participate in Upcoming Investor Conferences
09/02/2026
BOSTON, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced it [...]
DLH Reports Fiscal 2026 First Quarter Results
09/02/2026
ATLANTA, Feb. 09, 2026 (GLOBE NEWSWIRE) -- DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading provider of digital transformation and cybersecurity, systems engineering and integration, and science [...]
SafeSpace Global Corp. (OTCID: SSGC) Announces Investor Day to be held in Nashville, Tennessee on February 27, 2026
09/02/2026
Company to Meet with Investors and Financial Institutions During Event Knoxville, TN, Feb. 09, 2026 (GLOBE NEWSWIRE) -- SafeSpace Global Corporation (OTCID: SSGC) ("SafeSpace" or the "Company"), a provider of [...]
OraSure to Announce Fourth Quarter 2025 Financial Results and Host Earnings Call on February 25th
09/02/2026
BETHLEHEM, Pa., Feb. 09, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering fourth quarter 2025 financial results and certain business [...]
PetVivo Sets Fiscal Third Quarter 2026 Conference Call for Monday, February 16, 2026 at 5:00 p.m. ET
09/02/2026
MINNEAPOLIS, MN, US, Feb. 09, 2026 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc., including its wholly-owned subsidiary Petvivo Animal Health, Inc. (OTCQX: PETV; OTCID: PETVW), a leading biomedical company delivering [...]
Agomab Announces Closing of Initial Public Offering
09/02/2026
ANTWERP, Belgium, February 9, 2026 (GLOBE NEWSWIRE) – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab”), a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology [...]
DBV Technologies to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit
09/02/2026
Châtillon, France, February 9, 2025 DBV Technologies to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT) (the “ [...]
Earth Science Tech, Inc. (ETST), to Report Financial Results for Fiscal Third Quarter on February 17, 2026
09/02/2026
MIAMI, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC: ETST) (“ETST” or the “Company”), a strategic holding company focused on acquiring and scaling high-potential operating businesses, today announced [...]
LifeStance to Host Fourth Quarter and Full Year 2025 Earnings Conference Call on February 25, 2026
09/02/2026
SCOTTSDALE, Ariz., Feb. 09, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (NASDAQ: LFST), one of the nation’s largest providers of outpatient mental health care, will issue its fourth quarter and full year 2025 [...]
AB Science announced that the Food and Drug Administration (FDA) granted the status of Minor Use in Major Species (MUMS) for Masivet® in the treatment of canine mast cell tumors
09/02/2026
PRESS RELEASE AB SCIENCE ANNOUNCES THAT THE FDA HAS GRANTED THE STATUS OF MINOR USE IN MAJOR SPECIES DESIGNATION FOR MASIVET IN THE TREATMENT OF CANINE MAST CELL TUMORS AB SCIENCE PRESENTS PERSPECTIVE OF THE ANIMAL [...]
Ipsen - Janvier 2026 - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
09/02/2026
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social (conformément à l’article L.233-8 II du Code de commerce et à l’article 223-16 du Règlement Général de l’ [...]
AB Science annonce que la Food and Drug Administration (FDA) américaine a accordé le statut de Minor Use in Major Species (MUMS) au Masivet® dans le traitement des tumeurs mastocytaires chez le chien
09/02/2026
COMMUNIQUÉ DE PRESSE AB SCIENCE ANNONCE QUE LA FDA A ACCORDÉ LE STATUT DE “MINOR USE IN MAJOR SPECIES” (MUMS) AU MASIVET DANS LE TRAITEMENT DES TUMEURS MASTOCYTAIRES CHEZ LE CHIEN AB SCIENCE PRÉSENTE LES PERSPECTIVES DE [...]
Ipsen - January 2026 - Monthly information relative to the total number of voting rights and shares composing the share capital
09/02/2026
Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation [...]

Pages